FDA Reportedly Shelves Fast-Track Drug Review Voucher Program, Reuters Says
WASHINGTON — November 12, 2026. The U.S. Food and Drug Administration has shelved a special voucher program intended to accelerate certain drug approvals, according to Reuters reporting based on people familiar with the decision.
What the program was designed to do
The National Priority Voucher initiative, launched in June 2025, sought to reduce review timelines for drugs aligned with designated national priorities to as little as one or two months. Critics questioned whether such rapid decisions could undermine consistent scientific review or favor companies meeting administration priorities.
What the reported change means
Reuters describes the initiative as shelved, but that does not mean the FDA has stopped reviewing new medicines or that existing approvals are invalid. Standard regulatory review processes remain distinct from this special fast-track initiative.
Patients should not change prescribed treatments based on this administrative report. Brownstone Worldwide will monitor any formal FDA announcement and implications for drug developers and patients.
Source: Original reporting and official information.
Featured graphic is an editorial illustration, not a documentary photograph.
